AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration. The antibody-drug conjugate,

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing accessibility with lower prices. This inclusion comes amid competition and AstraZeneca facing investigations in China.

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move that will boost the British drugmaker’s sales in the country in the midst of an ongoing probe that’s ensnared some of its senior executives.

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY), would be added for reimbursement by state-run medical insurance in China,

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance scheme from January 1, as per a recent update from the National

AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, according to an update from the National Healthcare Security Administration.